Precision Medicine in Asthma Therapy

Overview

Journal Handb Exp Pharmacol

Specialty Pharmacology

Date 2022 Jul 19

PMID 35852633

Authors

Stefania Principe

Susanne J H Vijverberg

Mahmoud I Abdel-Aziz

Nicola Scichilone

Anke H Maitland-van der Zee

Affiliations

Soon will be listed here.

Abstract

Asthma is a complex, heterogeneous disease that necessitates a proper patient evaluation to decide the correct treatment and optimize disease control. The recent introduction of new target therapies for the most severe form of the disease has heralded a new era of treatment options, intending to treat and control specific molecular pathways in asthma pathophysiology. Precision medicine, using omics sciences, investigates biological and molecular mechanisms to find novel biomarkers that can be used to guide treatment selection and predict response. The identification of reliable biomarkers indicative of the pathological mechanisms in asthma is essential to unravel new potential treatment targets. In this chapter, we provide a general description of the currently available -omics techniques, focusing on their implications in asthma therapy.

Citing Articles

Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab.

van Dijk Y, Rutjes N, Golebski K, Sahin H, Hashimoto S, der Zee A Paediatr Drugs. 2023; 25(6):677-693.

PMID: 37658954 PMC: 10600295. DOI: 10.1007/s40272-023-00589-4.

References

I Abdel-Aziz M, Vijverberg S, Neerincx A, Kraneveld A, Maitland-van der Zee A . The crosstalk between microbiome and asthma: Exploring associations and challenges. Clin Exp Allergy. 2019; 49(8):1067-1086. PMC: 6852296. DOI: 10.1111/cea.13444. View

I Abdel-Aziz M, Brinkman P, Vijverberg S, Neerincx A, Riley J, Bates S . Sputum microbiome profiles identify severe asthma phenotypes of relative stability at 12 to 18 months. J Allergy Clin Immunol. 2020; 147(1):123-134. DOI: 10.1016/j.jaci.2020.04.018. View

Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S . Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016; 47(2):410-9. DOI: 10.1183/13993003.01359-2015. View

Akhabir L, Sandford A . Genome-wide association studies for discovery of genes involved in asthma. Respirology. 2011; 16(3):396-406. DOI: 10.1111/j.1440-1843.2011.01939.x. View

Anderson J, Chokesuwattanaskul S, Phelan M, Welting T, Lian L, Peffers M . H NMR Metabolomics Identifies Underlying Inflammatory Pathology in Osteoarthritis and Rheumatoid Arthritis Synovial Joints. J Proteome Res. 2018; 17(11):3780-3790. PMC: 6220363. DOI: 10.1021/acs.jproteome.8b00455. View

Arzenani M, Zade A, Ming Y, Vijverberg S, Zhang Z, Khan Z . Genomic DNA hypomethylation by histone deacetylase inhibition implicates DNMT1 nuclear dynamics. Mol Cell Biol. 2011; 31(19):4119-28. PMC: 3187370. DOI: 10.1128/MCB.01304-10. View

Bagnasco D, Massolo A, Bonavia M, Brussino L, Bucca C, Caminati M . The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life. Allergy. 2019; 75(6):1460-1463. DOI: 10.1111/all.14135. View

Bateman E, Bousquet J, Busse W, Clark T, Gul N, Gibbs M . Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study. Allergy. 2008; 63(7):932-8. DOI: 10.1111/j.1398-9995.2008.01724.x. View

Bel E, Ten Brinke A . New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!. Chest. 2017; 152(6):1276-1282. DOI: 10.1016/j.chest.2017.05.019. View

10.

Bell A, Deutsch E, Au C, Kearney R, Beavis R, Sechi S . A HUPO test sample study reveals common problems in mass spectrometry-based proteomics. Nat Methods. 2009; 6(6):423-30. PMC: 2785450. DOI: 10.1038/nmeth.1333. View

11.

Berger S, Kouzarides T, Shiekhattar R, Shilatifard A . An operational definition of epigenetics. Genes Dev. 2009; 23(7):781-3. PMC: 3959995. DOI: 10.1101/gad.1787609. View

12.

Bhakta N, Woodruff P . Human asthma phenotypes: from the clinic, to cytokines, and back again. Immunol Rev. 2011; 242(1):220-32. PMC: 3391010. DOI: 10.1111/j.1600-065X.2011.01032.x. View

13.

Bhavsar P, Ahmad T, Adcock I . The role of histone deacetylases in asthma and allergic diseases. J Allergy Clin Immunol. 2008; 121(3):580-4. DOI: 10.1016/j.jaci.2007.12.1156. View

14.

Boots A, Bos L, Van Der Schee M, van Schooten F, Sterk P . Exhaled Molecular Fingerprinting in Diagnosis and Monitoring: Validating Volatile Promises. Trends Mol Med. 2015; 21(10):633-644. DOI: 10.1016/j.molmed.2015.08.001. View

15.

Brinkman P, der Zee A, Wagener A . Breathomics and treatable traits for chronic airway diseases. Curr Opin Pulm Med. 2018; 25(1):94-100. DOI: 10.1097/MCP.0000000000000534. View

16.

Castro M, Zangrilli J, Wechsler M, Bateman E, Brusselle G, Bardin P . Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015; 3(5):355-66. DOI: 10.1016/S2213-2600(15)00042-9. View

17.

Charalampous T, Kay G, Richardson H, Aydin A, Baldan R, Jeanes C . Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection. Nat Biotechnol. 2019; 37(7):783-792. DOI: 10.1038/s41587-019-0156-5. View

18.

Ciprandi G, Tosca M, Silvestri M, Ricciardolo F . Inflammatory biomarkers for asthma endotyping and consequent personalized therapy. Expert Rev Clin Immunol. 2017; 13(7):715-721. DOI: 10.1080/1744666X.2017.1313117. View

19.

Condreay L, Chiano M, Ortega H, Buchan N, Harris E, Bleecker E . No genetic association detected with mepolizumab efficacy in severe asthma. Respir Med. 2017; 132:178-180. DOI: 10.1016/j.rmed.2017.10.019. View

20.

Desai M, Oppenheimer J . Elucidating asthma phenotypes and endotypes: progress towards personalized medicine. Ann Allergy Asthma Immunol. 2016; 116(5):394-401. DOI: 10.1016/j.anai.2015.12.024. View